Application value of alfacalcidol pulse therapy in treatment of end-stage renal disease with second-ary hyperparathyroidism

Abstract

Objective To study the application value of alfacalcidol pulse therapy in treatment of end-stage renal disease with secondary hyperparathyroidism. Methods Selected 50 patients with secondary hyperparathyroidism of end-stage renal disease as study object. All the patients were treated with hemodialysis treatment, and they were orally took 0.5 μg alfacalcidol after the treatment begins. The changes of blood phosphate (P), blood calcium (Ca2+ ), parathyroid hormone (PTH), and adverse reactions during treatment were compared between before and after treatment. Results After treatment, the levels of PTH and P significantly decreased, and the level of Ca2+ increased, the difference was statistically significant (P<0.05); during treatment, the patients had no liver function changes and gastrointestinal reactions, only two patients had high blood caluium, and all the patients completed the course of treatment. Conclusions Alfacalcidol pulse therapy in treatment of end-stage renal disease with secondary hyperparathyroidism can improve the levels of Ca2+ , P and PTH, reduce clinical symptoms, have higher safety and no obvious adverse reactions, which is worthy of clinical promotion and application. Key words: Alfacalcidol; End-stage renal disease; Hyperparathyroidism; Adverse reactions